Elevidys基因疗法药物

Search documents
“赢家通吃”格局强化市场聚焦巨头财报风暴,大摩看多标普500剑指7200点
智通财经网· 2025-07-22 00:30
Group 1 - The US stock market continues to show strength as major indices reach historical highs, driven by strong investor risk appetite and the performance of large tech stocks [1] - The S&P 500 index closed up 0.1% at 6305.60 points, marking a new record, while the Nasdaq 100 index rose 0.5%, also reaching a historical high [1] - Wells Fargo analyst Chris Harvey notes a "winner-takes-all" market trend, with large-cap companies benefiting from higher profit margins and expanding market shares, supported by long-term growth in the AI sector [1] Group 2 - The earnings season has shown mixed results, with Verizon's stock rising due to better-than-expected Q2 results and an upward revision of annual profit forecasts, while Domino's Pizza saw a reversal in early gains and closed down [4] - Morgan Stanley's strategy team remains optimistic about the US stock market, citing factors like profit growth momentum and positive operating leverage, maintaining a bullish forecast for the S&P 500 to reach 7200 points by mid-next year [4] - Goldman Sachs analysts highlight that a recent weakening of the dollar has provided a slight boost to S&P 500 earnings, offsetting some of the profit pressures from tariff policies [4] Group 3 - Trade policy uncertainties continue to loom over the market, with EU and US negotiators facing significant obstacles in tariff discussions, particularly regarding proposed 15% tariffs on European goods [5] - The automotive industry is at the center of the tariff storm, with Stellantis NV reporting a net loss of €2.3 billion in the first half of the year and canceling electric vehicle investment plans due to trade war costs [5] - Sarepta Therapeutics' stock has fallen to its lowest level since 2016, following the company's refusal to halt shipments of its Elevidys gene therapy linked to three death incidents, raising market concerns [5]